Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation by Eriksson, Oskar et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2019 
Thiol isomerase ERp57 targets and modulates the lectin pathway 
of complement activation 
Oskar Eriksson 
Joyce Chiu 
Philip J. Hogg 
John P. Atkinson 
M. Kathryn Liszewski 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Oskar Eriksson, Joyce Chiu, Philip J. Hogg, John P. Atkinson, M. Kathryn Liszewski, Robert Flaumenhaft, 
and Bruce Furie 
Thiol isomerase ERp57 targets andmodulates the lectin
pathway of complement activation
Received for publication,November 19, 2018, and in revised form, January 13, 2019 Published, Papers in Press, January 22, 2019, DOI 10.1074/jbc.RA118.006792
Oskar Eriksson‡1, Joyce Chiu§, X Philip J. Hogg§, John P. Atkinson¶, M. Kathryn Liszewski¶, Robert Flaumenhaft‡,
and X Bruce Furie‡2
From the ‡Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and HarvardMedical School, Boston,
Massachusetts 02115, the §Centenary Institute, National Health andMedical Research Council Clinical Trials Centre, Sydney
Medical School, University of Sydney, Sydney, New SouthWales 2006, Australia, and the ¶Department of Medicine/Rheumatology,
Washington University School of Medicine, St. Louis, Missouri 63110
Edited by Ruma Banerjee
ER protein 57 (ERp57), a thiol isomerase secreted from vascu-
lar cells, is essential for complete thrombus formation in vivo,
but other extracellular ERp57 functions remain unexplored.
Here, we employed a kinetic substrate-trapping approach to
identify extracellular protein substrates of ERp57 in platelet-
rich plasma. MS-based identification with immunochemical
confirmation combinedwith geneontology enrichment analysis
revealed that ERp57 targets, among other substrates, compo-
nents of the lectin pathway of complement activation:mannose-
binding lectin, ficolin-2, ficolin-3, collectin-10, collectin-11,
mannose-binding lectin-associated serine protease-1, andman-
nose-binding lectin-associated serine protease-2. Ficolin-3, the
most abundant lectin pathway initiator in humans, circulates as
disulfide-linked multimers of a monomer. ERp57 attenuated
ficolin-3 ligand recognition and complement activation by
cleaving intermolecular disulfide bonds in large ficolin-3multi-
mers, thereby reducing multimer size and ligand-binding affin-
ity. We used MS to identify the disulfide-bonding pattern in
ficolin-3 multimers and the disulfide bonds targeted by ERp57
and found that Cys6 and Cys23 in the N-terminal region of fico-
lin-3 form the intermolecular disulfide bonds in ficolin-3
multimers that are reduced by ERp57.Our results not only dem-
onstrate that ERp57 can negatively regulate complement activa-
tion, but also identify a control mechanism for lectin pathway
initiation in the vasculature. We conclude that extensive multi-
merization in large ficolin-3 multimers leads to a high affinity
for ligands and strong complement-activating potential and
that ERp57 suppresses complement activation by cleaving disul-
fide bonds in ficolin-3 and reducing its multimer size.
Among other functions, thiol isomerases catalyze the folding
of nascent proteins in the endoplasmic reticulum through the
oxidation, reduction, or isomerization of disulfide bonds (1).
Protein-disulfide isomerase (PDI)3 is the prototypic enzyme in
this protein family that includes about 20 members. They are
characterized by conserved thioredoxin-like structural folds
harboring a Cys-Gly-His-Cys (CGHC) motif (2). A subset of
known thiol isomerases are actively secreted from vascular cells
upon their activation (3, 4), and a role for some of these thiol
isomerases in thrombus formation has been established. PDI is
released from platelets and endothelial cells and is required for
platelet thrombus formation and fibrin deposition in vivo (5, 6).
ERp57 is a close homolog of PDI and is important for platelet
function and required for normal thrombus formation in vivo
(7–9). In addition, similar roles for ERp5 (10) and ERp72 (11,
12) are known. This group of enzymes are considered the vas-
cular thiol isomerases (13).
Themechanism bywhich thiol isomerases control thrombus
formation or their roles in other processes in the vasculature
are not well understood. To address these questions, we have
adapted a kinetic substrate trapping strategy to identify sub-
strates of extracellular thiol isomerases. Substitution of the
C-terminal cysteine in the CGHC active sites to alanine results
in a trapping variant that forms a stable covalent disulfide link
with its substrate (14). Using this methodology, we identified
plasma vitronectin as one of the substrates of PDI (15). Cleav-
age of one or two disulfide bonds in vitronectin by PDI enables
binding of vitronectin to 3 integrins on the endothelium and
support of thrombus formation.
In the current study, we extended this approach using the
kinetic substrate trapping strategy to identify extracellular tar-
gets of ERp57. Like PDI, ERp57 has four domains in the a-b-
b-a configuration, where the a and a domains have an active-
site CGHC motif (16, 17). ERp57 and PDI have 33% sequence
similarity. Among the ERp57 substrates identified were man-
nose-binding lectin (MBL), ficolin-2, ficolin-3, collectin-10,
collectin-11, mannose-binding lectin-associated serine prote-
ase-1 (MASP-1), andmannose-binding lectin-associated serine
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protease-2 (MASP-2). These proteins are among the compo-
nents of the lectin pathway of complement activation, one of
the three pathways that initiate the complement system. Fico-
lin-3, a multimeric pattern recognition molecule that is the
most abundant lectin pathway initiator in human plasma, is
susceptible to disulfide bond cleavage by ERp57. ERp57 reduces
large ficolin-3 multimers and attenuates lectin pathway initia-
tion by inhibiting target recognition by ficolin-3. Our findings
reveal that ERp57 targets complement activation via the lectin
pathway.
Results
The lectin pathway of complement activation is targeted by
ERp57
To identify vascular substrates of ERp57, we adapted the
kinetic substrate trapping strategy described for PDI (15). We
generated and purified recombinant ERp57 variants where
both of the CGHC active sites were mutated to CGHA, termed
ERp57-CACA (Fig. 1A). An inactive variant with both active
sites asAGHA, termed ERp57-AAAA, served as a negative con-
trol. These ERp57 variants were evaluated in the insulin reduc-
tion assay (Fig. 1B, left) and the di-eosin-GSSG assay (Fig. 1B,
right). ERp57-AAAAhad no enzymatic activity, and the activity
of ERp57-CACA was reduced. When added to activated plate-
let-rich plasma, the ERp57-CACA variant formed disulfide-
linked complexes with a number of substrates, as evidenced by
high-molecular weight complexes on unreduced gels (Fig. 1C,
left) that were resolved by reduction with 2-mercaptoethanol
(Fig. 1C, right).
The trapped substrates were identified by MS. A trapping
experiment was performed in platelet-rich plasma followed by
elution with DTT, thus releasing trapped substrates that were
disulfide-linked to ERp57-CACA. The ERp57-AAAA variant,
lacking a functional active site, served as negative control. Elu-
ates from ERp57-CACA and ERp57-AAAAwere directly com-
pared by MS. Proteins were detected in both samples, but we
Figure 1. Characterization of recombinant ERp57 variants and their interaction with protein substrates. A, recombinant ERp57 variants (1 g) were
subjected to SDS-PAGE and visualized with Coomassie Blue. These variants include 1) WT ERp57, containing 57CGHC60 and 406CGHC409 active sites located in
the a domain and adomain, respectively (ERp57-CCCC); 2) a trapping variant inwhich the C-terminal active-site cysteines aremutated to alanines, precluding
cleavage of the ERp57–substrate complex, 57CGHA60 and 406CGHA409 (ERp57-CACA); and 3) inactive ERp57 in which all four active-site cysteines are replaced
by alanines, 57AGHA60 and 406AGHA409 (ERp57-AAAA). B, reductase activities of the ERp57 variants evaluated in the insulin reduction assay (left) or in the
di-eosin-GSSG assay (right). Green, ERp57-CCCC; red, ERp57-CACA; blue, ERp57-AAAA; brown, control. Data are shown as mean  S.E. (error bars) from a
representative experiment with triplicatemeasurements. C, ERp57 variants (50g) were added to 1ml of platelet-rich plasma, precipitatedwith streptavidin-
agarose beads, centrifuged to remove platelets, and analyzed by gel electrophoresis and Western blotting. Left, unreduced. Right, reduced. Recombinant
ERp57 variants were detected with amouse anti-FLAG antibody. Representative blots are shown. D, a trapping experiment with ERp57-CACAwas performed
in platelet-rich plasma with ERp57-AAAA as negative control. After immunoprecipitation of the ERp57 variants, disulfide-linked substrates were eluted by
reduction with DTT. The eluates were precipitated with TCA and analyzed by MS. The graph shows gene ontology biological process enrichment analysis of
MS-identified proteins in the ERp57-CACA data set, using the plasma proteome as background. Enriched ontologies with a false discovery rate  0.05 are
shown, with selected ontologies indicated.
ERp57 regulates the lectin pathway
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focused on the 76 proteins exclusively detected in the ERp57-
CACA sample.We subjected the ERp57-CACAdata set to gene
ontology enrichment analysis (18, 19) using the PANTHER
database (20) and gene ontology biological process annotations,
with the plasma proteome (21) as background. The analysis
revealed an enrichment of the lectin pathway of complement
(GO:0001867, -fold enrichment 30, false discovery rate 0.0014)
(Fig. 1D). A manual search for components of the lectin path-
way (22) in theMS data set revealed that all components of this
pathwaywere detected with the ERp57-CACA trapping variant
except for ficolin-1 (Table 1), demonstrating that this pathway
is targeted by ERp57.
The lectin pathway is initiated by six different pattern recog-
nition molecules: MBL, ficolin-1, -2, and -3, and collectin-10
and -11, that recognize carbohydrate moieties on microorgan-
isms and damage-associated molecular patterns on altered-self
structures (22). Of these, ficolin-3 is the most abundant and
potent lectin pathway initiator in humans (23). Substrate trap-
ping ofMBL, ficolin-2, and ficolin-3 by ERp57-CACAwas con-
firmed by immunoblotting. These proteins circulate in plasma
as disulfide-linked multimers and display a ladder of bands
when analyzed on unreduced SDS gels (Fig. 2, A–D, top). In
contrast, under reducing conditions, only the monomers of
MBL, ficolin-2, and ficolin-3 were observed (Fig. 2, A–D, bot-
tom). ERp57-CACA selectively trapped large multimers of the
ficolins andMBL.When comparing densitometry lane profiles
on unreduced blots, a shift in apparent molecular weight was
seen only for the largest species, indicating that they form dis-
ulfide-linked complexes with the ERp57 trapping variant (Fig.
2,E–G). These results confirm the substrate identification from
MS and show that ERp57 targets themultimeric forms of lectin
pathway pattern recognition molecules circulating in plasma.
ERp57 attenuates ficolin-3–dependent lectin pathway
initiation
To determine whether ERp57 has functions that regulate
complement activation through the lectin pathway, we used an
ELISA with lectin pathway activators coated on the solid phase
and serum as a source of complement proteins. ERp57-CCCC
was added to the reactions in the presence of 10 M DTT, and
ligand recognition by MBL, ficolin-2, and ficolin-3 was evalu-
ated.MBL binding wasmonitored on amatrix consisting of the
yeast polysaccharidemannan (24) andwas not altered byERp57
(data not shown). ComparedwithMBL, ficolins have a different
ligand specificity and bind strongly to acetylated compounds,
such as acetylated BSA (25, 26). A time- and concentration-de-
pendent inhibition of ficolin-3 by ERp57 was observed, and
binding to the acetylated BSA matrix was reduced to 30% of
control (Fig. 3A). Reduction in ficolin-3 binding required the
CGHC active-site motifs; ERp57-AAAA had no effect (Fig. 3B).
In addition, ERp57-CCCC had a moderate but significant
inhibitory effect on ficolin-2 binding to acetylated BSA
(data not shown). These results demonstrated that ERp57
inhibits ligand recognition by the ficolin-3–dependent lectin
pathway.
Ficolin-3 circulates in complex with serine proteases (MASP-1
and MASP-2) that are activated through a conformational
change following target binding.WemonitoredMASP-1 activ-
ity by cleavage of the synthetic substrate VPR-AMC (27) when
ficolin-3 was captured on acetylated BSA. ERp57-CCCC
decreased VPR-AMC cleavage in a dose-dependent fashion
(Fig. 4A). No inhibition was seen with the inactive ERp57-
AAAA (Fig. 4B). A bar graph summarizes these results (Fig.
4D).
Initiation of the lectin pathway leads to activation of comple-
ment factors C2 andC4 byMASP-1 andMASP-2. Activated C2
and C4 in turn form a C3 convertase (C2aC4b) that activates
complement factorC3 and leads to propagation of complement
activation. The ELISA was used to measure downstream com-
plement activation on acetylated BSA, which is specific for fico-
lin-3 with only a minor contribution from ficolin-2 (26). The
effect of ERp57-CCCC on ficolin-3 binding and ficolin-3–
MASP activity was paralleled by a decrease in complement acti-
vation with a reduction in C4 deposition observed in the pres-
ence of ERp57 (Fig. 5A, left). Similarly, decreased C3 deposition
on acetylated BSA was observed in the presence of ERp57 (Fig.
5B, right). Taken together, ERp57 attenuates ficolin-3 target
recognition, the proteolytic activity of the ficolin-3–MASP
complex, and downstream complement activation.
ERp57 cleaves ficolin-3multimers by disulfide reduction
Circulating ficolin-3 forms a range of multimers, with the
largest species having biological activity (23). To determine
whether the suppressive effect of ERp57 on lectin pathway ini-
tiation was due to direct changes in ficolin-3 multimerization,
we performed SDS-PAGE and immunoblotting under nonre-
Table 1
Components of the lectin pathway detected by MS in ERp57-AAAA and ERp57-CACA samples
ERP57-AAAA ERP57-CACA Serum
concentration (22)Unique peptides Total peptides Unique peptides Total peptides
g/ml
Ficolin-3 0 0 6 20 25
MBL 0 0 11 13 1
Ficolin-2 0 0 5 6 5
MASP-1a 0 0 5 6 7.5
MASP-2b 0 0 3 3 0.5
Collectin-10 0 0 3 3 0.3
Collectin-11 1 1 3 3 0.3
Ficolin-1 0 0 0 0 0.3
a The MASP-1 gene also encodes two other circulating proteins generated by alternative splicing, the protease MASP-3 and the protein MAp44 (MAP-1), which acts as a
negative regulator of the lectin pathway. Their serum concentrations have been estimated to be 6 g/ml and 0.25–1 g/ml, respectively.
b The MASP-2 gene is alternatively spliced to generate the protein MAp19 (sMAP), a possible negative regulator of the lectin pathway with an estimated serum concentra-
tion of 0.2 g/ml.
ERp57 regulates the lectin pathway
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ducing conditions. When serum was incubated with ERp57-
CCCC, large ficolin-3 multimers disappeared with a con-
comitant increase in intermediately sizedmultimeric species
(Fig. 6, A and B). ERp57-AAAA had no effect on the multi-
mer pattern. The shift in multimerization indicated that
ficolin-3 was cleaved by ERp57. ERp57 also cleaved ficolin-2
multimers, whereas minimal MBL cleavage was seen (data
not shown).
Ficolin-3 purified from serum showed multimeric forms up
to 21-mer on unreduced gels. When incubated with ERp57-
CCCC, we observed a shift inmultimer size in purified ficolin-3
(Fig. 6C, right). As ficolin-3 forms multimers through disulfide
bonds, we hypothesized that ficolin-3 cleavage by ERp57
occurred through disulfide bond reduction and used biotin-
conjugated maleimide (MPB) to label free thiols (Fig. 6C, left).
ERp57 increased MPB incorporation into ficolin-3, an effect
that was correlated to the decrease in multimer size. On unre-
duced gels, MPB labeling of ficolin-3 species of intermediate
sizes was observed, indicating that these were formed after
reductive cleavage of large multimers.
ERp57 cleaves ficolin-3 by reduction of intersubunit disulfide
bonds formed by the cysteines Cys6 and Cys23
The ficolin-3 monomer contains 8 cysteine residues. Two
cysteines (Cys6 and Cys23) near the N terminus have been pre-
dicted to mediate multimerization through intermolecular
disulfide bonds with other subunits (29), but the specific mul-
timerization pattern in native ficolin-3 is not known. We used
MS to detect disulfide-bridged tryptic peptides in order to map
the specific intermolecular disulfide bonds in ficolin-3. Pep-
Figure 2. Immunoblotting against identified putative substrates. Trapping experiments were performed in platelet-rich plasma with ERp57-CACA or
ERp57-AAAA (50g). Sampleswere analyzedbygel electrophoresis andWesternblottingunder nonreducing (top) or reducing conditions (bottom) usinggoat
anti-MBL (A), goat anti-ficolin-2 (B), goat anti-ficolin-3 (C), and mouse anti-FLAG (D) antibodies. E–G, the unreduced blots shown in A–C were analyzed by
densitometry, and the lane profiles of platelet-rich plasma (green) and ERp57-CACA (blue) were overlaid. E, MBL; F, ficolin-2; G, ficolin-3. Arrows indicate
multimers with a shift in molecular weight indicative of complex formation with ERp57-CACA. n 3; representative experiments are shown.
ERp57 regulates the lectin pathway
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tides bridged by disulfides connecting Cys6 to Cys6 and Cys23
to Cys23were detected in ficolin-3 dimers, trimers, and higher
oligomeric forms but not in the ficolin-3 monomer (Fig. 7).
Monomeric ficolin-3 contained an intramolecular disulfide
bond between Cys6 and Cys23. Cys6 and Cys23 were also linked
in a disulfide bond in multimeric ficolin-3, which has to be
intermolecular, as ficolin-3 with an intramolecular Cys6–Cys23
disulfide cannot be linked to other ficolin-3 subunits. No other
intermolecular disulfide bonds were found. We conclude that
ficolin-3 multimers are assembled through a mixture of Cys6–
Cys6, Cys23–Cys23, and Cys6–Cys23 intermolecular disulfide
bonds. ERp57 cleaves ficolin-3 multimers by reduction of these
disulfide bonds.
Estimation of the redox potential of ficolin-3multimers
To assess the properties of the ficolin-3 intermolecular disul-
fide bonds involved in multimerization, purified serum fico-
lin-3 was equilibrated in GSH redox buffers with varying ratios
of reduced (GSH) to oxidized (GSSG) glutathione (GSH2/
GSSGratio).Weusedmultimer distribution as an indirectmea-
sure of formation of the Cys6–Cys6, Cys23-Cys23, and Cys6–
Cys23 intermolecular disulfide bonds and quantified the
Figure 3. ERp57 inhibits ficolin-3 ligand recognition. A, the binding of ficolin-3 to acetylated BSA was detected using an ELISA. Diluted serum was
preincubated for 5minwithERp57 in thepresenceof 10MDTTandadded toplates coatedwith0.5g/ml acetylatedBSA for the times indicated.Green, serum
alone; red, DTT; blue, 0.1M ERp57-CCCC; brown, 0.5M ERp57-CCCC. B, ficolin-3 binding to acetylated BSA-coated plates was performed as above. ERp57 and
PDI variants were added as indicated, and plates were incubatedwith samples for 30min at 37 °C. Binding of ficolin-3 is shown for ERp57-CCCC, ERp57-AAAA,
and PDI-CCCC. n 3–5; data are presented asmean S.E. (error bars). *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001 (one-way ANOVAwith Dunnett’s
post-test correction).
Figure4. ERp57attenuates theserineproteaseactivityof the ficolin-3–MASPcomplex.Ficolin-3–MASPcomplexeswere captured for 30minat 37 °C from
1% serum on plates coated with 5 g/ml acetylated BSA. The proteolytic activity of the captured complexes was evaluated by cleavage of the fluorogenic
substrate VPR-AMC. A, ERp57-CCCC. Green, serum alone; red, DTT; blue, 0.1 M ERp57-CCCC; brown, 0.5 M ERp57-CCCC; black, serum in the absence of
acetylated BSAmatrix. B, ERp57-AAAA. Green, serum alone; red, DTT; yellow, 0.1 M ERp57-AAAA; orange, 0.5 M ERp57-AAAA; black, serum in the absence of
acetylated BSA matrix. C, PDI-CCCC. Green, serum alone; red, DTT; light purple, 0.1 M PDI-CCCC; dark purple, 0.5 M PDI-CCCC; black, serum in the absence
of acetylatedBSAmatrix.D, bar graph showing themean S.E. (error bars) of four experiments. *,p0.05; **,p0.01; ***,p0.001; ****,p0.0001 (one-way
ANOVA with Dunnett’s post-test correction). RFU, relative fluorescence units.
ERp57 regulates the lectin pathway
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abundance of each multimer compared with ficolin-3 without
GSH. A shift in ficolin-3 multimerization and a gradual disap-
pearance of large multimers occurred at increasing ratios of
reduced to oxidized GSH, demonstrating reduction of the
intermolecular disulfide bonds (Fig. 8,A andB).When the frac-
tion of reduced to oxidized multimers was plotted against the
GSH2/GSSG ratio, the redox potentials could be calculated
from the obtained equilibrium constants. These were found to
be 175 mV for the 21-mer, 188 mV for the 18-mer, 194
mV for the 15-mer, and207mV for the 12-mer (Fig. 8C). This
demonstrates that the redox potentials of ficolin-3 multimers
are a function ofmultimer size, with the largest ficolin-3 species
having the highest redox potential.
Discussion
Studies in mouse models have revealed an important role for
extracellular ERp57 in thrombus formation (7–9). Additional
functions of extracellular ERp57 have been proposed. A role for
thiol–disulfide exchangemediated by ERp57 in sperm–gamete
fusion has been reported (30), and ERp57was recently shown to
modulate the activity of transglutaminase 2 secreted by endo-
thelial cells (31).
In the current study, we present evidence that extracellular
ERp57 can also regulate complement initiation. Based upon a
substrate trapping strategy and gene ontology enrichment anal-
ysis, we identified the lectin pathway of complement activation
as a pathway regulated by ERp57. We demonstrate that ERp57
targets plasma ficolin-3, the most abundant lectin pathway ini-
tiator in humans (23), and attenuates ficolin-3–dependent
complement activation by cleaving large ficolin-3 multimers.
Our results thus show that in addition to modulating throm-
bus formation, an additional function of ERp57 in the vascula-
ture may be to regulate complement initiation. In agreement
with these findings, a suppressive effect of the protein reductant
thioredoxin on the late stages of complement activation was
demonstrated, suggesting a general role of redox reactions in
complement regulation. Thioredoxin did not affect the lectin
pathway, indicating a nonoverlapping role with ERp57 in com-
plement regulation (32).
Complement activation initiates a potent host defense path-
way that leads to destruction and removal of its presumably
foreign target. Damaging mutations in complement regulators
in humans are associated with conditions characterized by tis-
sue destruction mediated by autologous complement attack,
such as atypical hemolytic uremic syndrome (33). These obser-
vations indicate that it is critical for host cells to protect them-
selves from complement recognition. Based on our results, we
propose that ERp57 protects the vasculature from comple-
ment-mediated damage and serves to limit recognition by the
lectin pathway. However, ligands for ficolin-3 are not well-
characterized. Ficolin-3 can recognize late apoptotic cells (34),
but its potential to interact with host cells in the vasculature
remains to be determined. Nevertheless, in accord with this
hypothesis, platelets and endothelial cells are known to express
high levels of complement regulators on their surface (35) (36).
Regulation of complement activation by vonWillebrand factor
demonstrates that a factor that is prothrombotic can also serve
to limit complement attack on host cells (37, 38).
The kinetics of ERp57 action on ficolin-3 are slow as mea-
sured in our in vitro studies. The relative concentrations of the
enzyme and substrate, whether ERp57 acts on other critical
substrates in the lectin pathway or whether ERp57 requires
chaperones for enhancing the rate of inactivation, need to be
explored in more physiologic systems—perhaps in future stud-
ies using an animal model. A challenge for such studies will be
the significant differences in the lectin pathway between mice
and humans and the fact that the gene encoding ficolin-3 is
inactivated to a pseudogene in the rodent lineage (39). Instead,
MBL is the dominating lectin pathway trigger in mice, with the
main mouse MBL variant MBL-C having up to 100-fold higher
plasma concentration than MBL in humans (40). In this con-
text, it should be noted that ERp57 did not affectMBL function
in our studies.
The biological activity of lectin pathway pattern recognition
molecules is a function of their multimer size. Multimeric spe-
cies show a high affinity for ligands due to their multiple lectin
domains compared with a single lower-affinity binding site in
the monomeric subunits (41). MASPs preferentially interact
with large multimers (42). These conclusions are mostly based
on studies on MBL but are likely to apply to ficolins as well,
given their structural similarity. Ficolin-3 forms up to 21-mers
of the basic subunit, compared with MBL (42) and ficolin-2
(23), which assemble into 9-mers and 12-mers, in accordance
with observations that ficolin-3 is the most potent lectin path-
way activator (23). Our results suggest a novel mechanism to
inhibit the initiation of the lectin pathway through reductive
cleavage of multimeric ficolin-3 by ERp57 into smaller inactive
forms.Multimer cleavage as ameans to control protein activity
Figure 5. ERp57attenuates ficolin-3-dependent complement activation.
Diluted sera and ERp57 including DTT were added to plates coated with 0.5
g/ml acetylated BSA for the indicated time points at 37 °C. Complement
activation was assessed by developing plates for deposition of complement
components C4 (A) or C3 (B).Green, serumalone; red, DTT; blue, 0.1MERp57-
CCCC; brown, 0.5 M ERp57-CCCC. n 3; data are presented as mean S.E.
(error bars). *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001 (one-way
ANOVA with Dunnett’s post-test correction).
ERp57 regulates the lectin pathway
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is exemplified by proteolytic cleavage of vonWillebrand factor
by ADAMTS13, which is essential to prevent intravascular
thrombosis (43). Disulfide reduction has been proposed as an
additional mechanism to control von Willebrand factor multi-
mer size (44, 45). Hence, cleavage of disulfide bonds may be a
general mechanism to regulate multimeric proteins.
Our MS analyses revealed that the two N-terminal cysteines
Cys-6 and Cys-23 form the intermolecular disulfide bonds that
mediatemultimerization in native ficolin-3. Estimation of their
redox potential showed a multimerization-dependent effect,
indicative of ERp57 favoring the large biologically active fico-
lin-3 species. A feature of intermolecular disulfide bonds is the
tensile strain that is imposed on these bonds. Force-induced
strain can destabilize the oxidized state to facilitate disulfide
bond cleavage (46, 47).Mechanical strain in large ficolin-3mul-
timers could be an explanation for the susceptibility of these
intermolecular disulfide bonds to reduction and the reasonwhy
ERp57 preferentially cleaves highly multimeric ficolin-3.
In conclusion, our results demonstrate a novel role for ERp57
as a regulator of the lectin pathway of complement activation.
Cleavage of intermolecular disulfide bonds in the multimeric
pattern recognition molecule ficolin-3 by ERp57 prevents
ligand recognition and complement initiation through this
pathway. This study reveals novel functions of a vascular thiol
isomerase and adds to the list of proteins regulated through
allosteric disulfide bonds (48).
Figure 6. ERp57 alters ficolin-3 multimer distribution by disulfide reduction. A, serum was incubated with ERp57 variants and 10 M DTT for 30 min at
37 °C. Samples were analyzed for ficolin-3 multimerization after separation in unreduced SDS gels and immunoblotting with goat anti-human ficolin-3
antibodies (top). ERp57 variants were detected via their FLAG epitope to demonstrate that equal amounts were present in the reactions at the respective
concentrations (bottom). B, densitometry analysis of the ficolin-3 immunoblot shown in A. Green, serum alone; red, DTT; light blue, 0.1 M ERp57-CCCC; dark
blue, 0.5MERp57-CCCC; yellow, 0.1MERp57-AAAA; orange, 0.5MERp57-AAAA.C, purified ficolin-3 (25g/ml)was incubatedwith 0.5MERp57 (30g/ml)
in the absence or presence of 5 M DTT for 15 min and then labeled with MPB. Samples were analyzed by gel electrophoresis and Western blotting. MPB
incorporation was detected using horseradish peroxidase–labeled streptavidin (left) and ficolin-3 with goat anti-human ficolin-3 antibodies (right). Asterisks
indicate ERp57 variants that are also labeled by MPB. Unreduced (top) and reduced gels (bottom) are shown. D, densitometry analysis of the ficolin-3 immu-
noblot shown in C. Green, serum alone; red, 0.5M ERp57-CCCC; blue, DTT; brown, DTT and 0.5M ERp57-CCCC. n 3; representative experiments are shown.
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Experimental procedures
Materials
Goat anti-human ficolin-3 (AF2367, R&D Systems), biotiny-
lated goat anti-human ficolin-3 (BAF2367, R&D Systems), goat
anti-human MBL (AF2307, R&D Systems), biotinylated goat
anti-human MBL (BAF2307, R&D Systems), goat anti-human
ficolin-2 (AF2428, R&D Systems), biotinylated goat anti-hu-
man ficolin-2 (BAF2428, R&D Systems), biotinylated rabbit
anti-human C4b (11254-05021, AssayPro), goat anti-human
C3 (A213, Complement Technology), and mouse anti-FLAG
(8146, Cell Signaling Technology) were purchased from com-
mercial sources. Platelet-rich plasma and serum were obtained
from healthy donors. The serum was pooled, aliquoted, and
stored at 80 °C until use. All blood donors provided
informed consent, and the study was approved by the Beth
Israel Deaconess Medical Center Committee on Clinical
Figure 7. Ficolin-3 multimerization is mediated by disulfide bonds between the N-terminal cysteines Cys6 and Cys23. N-terminal domain disulfide-
linked peptides involving Cys6 and Cys23 were quantified in purified ficolin-3 subjected to a single alkylation step with 12C-IPA and separated by gel electro-
phoresis inunreducedgels. Ficolin-3monomers, dimers, trimers, tetramers, andhigher-ordermultimerswereexcised fromthegel andanalyzedbyMS. Peptide
abundance is expressed relative to the invariant peptide linked by Cys63 and Cys87 in the collagen-like domain of ficolin-3. Black, monomer; green, dimer; red,
trimer; blue, tetramer; brown, multimeric. A, N-terminal ficolin-3 disulfide-linked peptides involving Cys6 and Cys23. B, aberrant ficolin-3 disulfide-linked
peptides involving Cys6 and Cys23. Note the difference in the magnitude of the y axis of about 100-fold.
Figure 8. Estimation of the redox potential of ficolin-3multimers. A, purified ficolin-3was equilibrated in nitrogen-flushedGSH buffers with varying ratios
of reduced to oxidized glutathione (GSH2/GSSG ratio) for 16 h at 25 °C, pH 7. Reactions were stopped by alkylation with iodoacetamide, and ficolin-3
multimerization as ameasureof the redox state of the intermolecular disulfidebondswas analyzedbyunreducedSDS-PAGEandWesternblotting. GSH2/GSSG
ratios are indicated above the gel image, and multimer size is shown to the left. n 2; a representative blot is shown. B, the abundance of ficolin-3 21-mers,
18-mers, 15-mers, and 12-mers was quantified by densitometry at different GSH2/GSSG ratios and expressed as percentage of ficolin-3 abundance in the
absence of GSH. Error bars, S.E. (error bars). Shown are ficolin-3 21-mer (green), 18-mer (red), 15-mer (blue), 12-mer (brown). C, the fractions of reduced ficolin
21-mer, 18-mer, 15-mer, and 12-mer were plotted against the GSH2/GSSG ratio and fitted to Equation 1. Redox potentials were determined from Equation 2
using the calculated equilibrium constants. Shown are ficolin-3 21-mer (green), 18-mer (red), 15-mer (blue), and 12-mer (brown).
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Investigations and is in compliance with the Helsinki princi-
ples. Other chemicals and reagents were from Sigma-Al-
drich unless noted otherwise.
Kinetic mechanism–based substrate trapping
These experiments were performed according to Bowley et
al. (15) with modifications. The cDNA of human ERp57 was
cloned into the pT7-FLAG-SPB expression vector and used
to generated three classes of recombinant ERp57 constructs
using site-directed mutagenesis: 1) WT ERp57, containing
57CGHC60 and 406CGHC409 active sites located in the a domain
and a domain, respectively (ERp57-CCCC); 2) the trapping
variant in which an active-site cysteine is mutated to alanine,
precluding cleavage of the ERp57–substrate complex,
57CGHA60 and 406CGHA409 (ERp57-CACA); and 3) inactive
ERp57 inwhich cysteineswere replaced by alanines, 57AGHA60
and 406AGHA409 (ERp57-AAAA). The proteinswere expressed
in BL21 Escherichia coli bacteria and purified by two cycles
of affinity chromatography, using streptavidin-coated agarose
beads (Thermo Fisher) and then agarose beads conjugated to a
monoclonal FLAG antibody. The purity of the recombinant
proteins was assessed by Coomassie staining, and the catalytic
function was assessed by insulin reduction (49) and di-eosin-
GSSG (50) assays.
For the kinetic trapping experiments, platelet-rich plasma
anticoagulated with 4% citrate was obtained from blood
donors. ERp57 variants (50 g) were reduced with DTT and
excess DTT removed with Zeba desalting columns (Thermo
Fisher). Prereduced ERp57 variants were added to 1ml of plate-
let-rich plasma substituted with a 5 mM concentration of the
fibrin polymerization inhibitor Gly-Pro-Arg-Pro, and the reac-
tionswere activatedwith 0.4 units/ml thrombin.After proceed-
ing for 3 min, reactions were stopped with hirudin and N-
ethylmaleimide, and ERp57 complexed to substrates was
precipitated using streptavidin-coated agarose beads. Proteins
were eluted from the beads by boiling in sample buffer and then
analyzed by SDS-PAGE andWestern blot analysis under either
nonreducing or reducing conditions. For MS analysis, a trap-
ping experiment was performed with ERp57-CACA and
ERp57-AAAA. Disulfide-linked substrates were eluted with 10
mM DTT, and the eluate was precipitated with TCA and then
subjected to LC/MS/MS analysis on an LTQ Orbitrap Velos
Pro ion-trap mass spectrometer (Thermo Fisher Scientific)
after trypsin digestion. Peptides were detected, isolated, and
fragmented to produce a tandem mass spectrum of specific
fragment ions for each peptide. Peptide sequences were deter-
mined by matching protein databases with the acquired frag-
mentation pattern with Sequest (Thermo Fisher Scientific).
Solid-phase lectin pathway assays
For functional assessment of the lectin pathway, a solid-
phase ELISA format was used. Maxisorp 96-well plates were
coated overnight at 4 °C with 0.5 g/ml acetylated BSA as a
ligand for ficolin-2 (25) and ficolin-3 (26) and with 10 g/ml
mannan as a ligand forMBL (24). Plates were then washed with
TBS, 0.05% Tween 20 with 5 mM CaCl2 (TBS-T-Ca) and
blocked with Veronal-buffered saline (Boston Bioproducts)
supplementedwith 2mMCaCl2, 2mMMgCl2, and 0.05%Tween
20 (VBS-T). After blocking and washing of plates, serum was
diluted 1:100 in VBS-T andmixedwith ERp57 variants reduced
with 10 M DTT. Samples were preincubated for 5 min at 37 °C
before theywere added to the plates and incubated at 37 °C for the
indicated times. Binding of ficolin-2, ficolin-3, or MBL was
detected using biotinylated antibodies and horseradish
peroxidase–conjugated N-avidin (Thermo Fisher). The plates
were developed using True Blue Peroxidase substrate (Seracare),
terminated with 1 M HCl, and absorbances were read at 450 nm
using a Spectramax plate reader. No binding of ficolin-2 and fico-
lin-3 was observed to unmodified BSA or to mannan, and MBL
bound specifically tomannan but not to acetylated or unmodified
BSA.
Ficolin-3–mediated complement activation was assessed
using an ELISA with acetylated BSA-coated plates by measur-
ing deposition of complement components C4 and C3. Serum
diluted 1:100 was mixed with ERp57 variants and DTT before
being added to the plates. To minimize interference from the
alternative and classical pathways of complement activation,
serum was preincubated for 5 min on ice with 0.1 mg/ml sodium
polyethanol sulfate, an inhibitor of the alternative pathway and
classical pathway at these concentrations. The lectin pathway was
preserved (51). Sodium polyethanol sulfate did not affect ficolin-3
binding, andnoC4orC3depositionoccurredonunmodifiedBSA
in the presence of sodium polyethanol sulfate.
The proteolytic activity of the ficolin-3–MASP complexes
was assessed by cleavage of the fluorogenic substrate N-tert-
butoxycarbonyl-VPR-AMC (R&D Systems), which is cleaved
by MASP-1 (27). Ficolin-3–MASP-1 complexes were captured
on acetylated BSA-coated plates (5 g/ml) from serum diluted
in VBS-T with or without ERp57 variants and DTT for 30 min
at 37 °C. Plates were washed, and VPR-AMC diluted to 200 M
in VBS-T was added. Substrate cleavage was monitored on a
Biotek fluorescent plate reader with excitation at 380 nm and
emission at 460 nm.
Purification of ficolin-3
Ficolin-3 was purified from serum obtained from the blood
of donors (28). CaCl2 (10mM)was added to citrated plasma and
clotted with 10mM, and the supernatant was precipitated using
PEG with a 4–8% cut-off. The pellet was dissolved in TBS-T-
Ca, and ficolin-3was affinity-purified on a column of acetylated
human serum albumin conjugated to agarose. Protein was
eluted with 1 M sodium acetate and dialyzed against TBS-Ca.
Co-purified IgG and IgM were removed using protein A- and
anti-IgM-agarose columns, and the eluate was concentrated
using Vivaspin 6 spin columns (GE Healthcare) and then ali-
quoted and stored at80 °C.
MS analysis of ficolin-3
For analysis of disulfide pairing by MS, purified ficolin-3 (10
g) was alkylated with 5 mM 2-iodo-N-phenylacetamide (12C-
IPA) in the dark for 1 h at 25 °C and resolved on SDS-PAGE in
the absence of reducing agent. The gel slices were washed and
dried before digestion of proteins with 12 ng/l chymotrypsin
(Roche Applied Science) in 25 mM NH4CO2 and 10 mM CaCl2
for 4 h at 37 °C followed by 12 ng/l trypsin (Promega) over-
night at 25 °C. Reactions were stopped by adding 5% (v/v) for-
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mic acid, and peptides were eluted from the gel slices with 5%
formic acid and 50% (v/v) acetonitrile.
Using a Thermo Fisher Scientific Ultimate 3000 HPLC, pep-
tides in 0.1% formic acid (final volume 12 l) were resolved on
a 35 cm 75 m C18 reverse phase analytical column using a
2–35% acetonitrile gradient over 22 min with a flow rate of 300
nl/min. The peptides were ionized by electrospray ionization at
	2.0 kV. TandemMS analysis was carried out on a Q-Exactive
Plus mass spectrometer (Thermo Fisher Scientific) using CID
fragmentation. The data were searched using Mascot (Matrix
Science) against the Uniprot database. Ion abundance of pep-
tides was calculated as described (52). Briefly, extracted ion
chromatograms were generated using XCalibur Qual Browser,
and area was calculated using the automated peak detection
function. The abundance of disulfide-linked peptides was
expressed as a ratio relative to an invariant disulfide-linked pep-
tide between Cys63 and Cys87.
Estimation of the redox potential of ficolin-3multimers
Purified ficolin-3 (50 g/ml) was incubated with nitrogen-
flushed PBS, pH 7, with 1 mM EDTA and varying concentra-
tions of reduced (GSH) and oxidized (GSSG) glutathione for
16 h at 25 °C. Reactions were terminated by alkylation with 25
mM iodoacetamide, and ficolin-3multimerizationwas analyzed
by SDS-PAGE in the absence of reducing agent and Western
blotting. The results were expressed as the ratio of reduced to
oxidized protein and fitted to Equation 1,
R 

GSH2/GSSG
Keq GSH2GSSG
(Eq. 1)
where R is the fraction of reduced protein at equilibrium and
Keq is the equilibrium constant. The standard redox poten-
tials (E0) of the intermolecular disulfide bonds in ficolin-3
multimers were calculated using the Nernst equation (Equa-
tion 2),
E0  EGSSG
0 
RT
2F
InKeq (Eq. 2)
using a value of 240 mV for the standard redox potential of
the GSSG disulfide bond.
Statistics
Results are presented as mean  S.E. To test for difference
between experimental conditions, one-wayANOVAwithDun-
nett’s post-test correction was used. p  0.05 was considered
statistically significant. p values are indicated as follows: *, p
0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001.
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